Pieter Sonneveld

Summary

Affiliation: Erasmus MC
Country: The Netherlands

Publications

  1. ncbi request reprint Cost determinants in aggressive non-Hodgkin's lymphoma
    Michel van Agthoven
    Institute for Medical Technology Assessment, Erasmus MC, University Medical Center Rotterdam, PO Box 1738, 3000 DR Rotterdam, The Netherlands
    Haematologica 90:661-71. 2005
  2. doi request reprint Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial
    Pieter Sonneveld
    Erasmus Medical Center, Rotterdam, The Netherlands
    J Clin Oncol 30:2946-55. 2012
  3. ncbi request reprint The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis
    Bronno van der Holt
    Department of Hematology, Erasmus MC, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    Blood 106:2646-54. 2005
  4. ncbi request reprint European myeloma network: the value of collaborative research
    Pieter Sonneveld
    Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands
    Acta Haematol 114:14-7. 2005
  5. doi request reprint Dealing with neuropathy in plasma-cell dyscrasias
    Pieter Sonneveld
    Department of Hematology, Erasmus Medical Center, Erasmus University, Rotterdam, The Netherlands
    Hematology Am Soc Hematol Educ Program 2010:423-30. 2010
  6. ncbi request reprint Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial
    Pieter Sonneveld
    Erasmus Medical Center Rotterdam, The Netherlands
    Haematologica 92:928-35. 2007
  7. doi request reprint Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial
    Evelien Kneppers
    Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands
    Blood 118:2413-9. 2011
  8. doi request reprint Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study
    Bob Lowenberg
    Erasmus University Medical Center, Rotterdam, The Netherlands
    Blood 115:2586-91. 2010
  9. ncbi request reprint Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: a phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON)
    Leo F Verdonck
    Department of Hematology, University Medical Center, Utrecht, The Netherlands
    Blood 109:2759-66. 2007
  10. ncbi request reprint Vault mobility depends in part on microtubules and vaults can be recruited to the nuclear envelope
    Arend van Zon
    Department of Hematology, Erasmus Medical Center, PO Box 1738, 3000 DR Rotterdam, The Netherlands
    Exp Cell Res 312:245-55. 2006

Detail Information

Publications94

  1. ncbi request reprint Cost determinants in aggressive non-Hodgkin's lymphoma
    Michel van Agthoven
    Institute for Medical Technology Assessment, Erasmus MC, University Medical Center Rotterdam, PO Box 1738, 3000 DR Rotterdam, The Netherlands
    Haematologica 90:661-71. 2005
    ..Given the need for economic evaluations, we analyzed whether the IPI and the presence of B-symptoms (night sweats, fever, weight loss) can identify subgroups of patients with favorable or unfavorable cost profiles...
  2. doi request reprint Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial
    Pieter Sonneveld
    Erasmus Medical Center, Rotterdam, The Netherlands
    J Clin Oncol 30:2946-55. 2012
    ..We investigated whether bortezomib during induction and maintenance improves survival in newly diagnosed multiple myeloma (MM)...
  3. ncbi request reprint The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis
    Bronno van der Holt
    Department of Hematology, Erasmus MC, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    Blood 106:2646-54. 2005
    ..The role of strategies aimed at inhibitory P-gp and other drug-resistance mechanisms continues to be defined in the treatment of patients with AML...
  4. ncbi request reprint European myeloma network: the value of collaborative research
    Pieter Sonneveld
    Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands
    Acta Haematol 114:14-7. 2005
    ....
  5. doi request reprint Dealing with neuropathy in plasma-cell dyscrasias
    Pieter Sonneveld
    Department of Hematology, Erasmus Medical Center, Erasmus University, Rotterdam, The Netherlands
    Hematology Am Soc Hematol Educ Program 2010:423-30. 2010
    ..Adequate pain management and supportive care require a multidisciplinary approach involving the treating physician, expert nursing staff, and a neurologist as clinically indicated...
  6. ncbi request reprint Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial
    Pieter Sonneveld
    Erasmus Medical Center Rotterdam, The Netherlands
    Haematologica 92:928-35. 2007
    ..The Dutch-Belgian HOVON group performed a randomized phase 3 trial to compare single non-myeloablative intensive treatment with double, intensive treatment in previously untreated patients with multiple myeloma (MM)...
  7. doi request reprint Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial
    Evelien Kneppers
    Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands
    Blood 118:2413-9. 2011
    ..This trial was registered at www.trialregister.nl as #NTR1645...
  8. doi request reprint Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study
    Bob Lowenberg
    Erasmus University Medical Center, Rotterdam, The Netherlands
    Blood 115:2586-91. 2010
    ..The HOVON-43 study is registered at The Netherlands Trial Registry (number NTR212) and at http://www.controlled-trials.com as ISRCTN77039377...
  9. ncbi request reprint Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: a phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON)
    Leo F Verdonck
    Department of Hematology, University Medical Center, Utrecht, The Netherlands
    Blood 109:2759-66. 2007
    ..These data suggest that I-CHOP might be preferable to standard CHOP in younger patients with low-intermediate-risk aggressive NHL...
  10. ncbi request reprint Vault mobility depends in part on microtubules and vaults can be recruited to the nuclear envelope
    Arend van Zon
    Department of Hematology, Erasmus Medical Center, PO Box 1738, 3000 DR Rotterdam, The Netherlands
    Exp Cell Res 312:245-55. 2006
    ..We hypothesize that a subset of vaults moves directionally via microtubules, possibly towards the nucleus...
  11. ncbi request reprint Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study
    Christine M Segeren
    Erasmus Medical Center Rotterdam, The Netherlands
    Blood 101:2144-51. 2003
    ..However, it did not result in a better EFS and OS...
  12. pmc CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age
    Marry M van den Heuvel-Eibrink
    Department of Hematology, P O Erasmus MC, Dr Molewaterplein 40, 3015 GJ, Rotterdam, The Netherlands
    Ann Hematol 86:329-37. 2007
    ..When adjusted for other prognostic actors, only CD34-related MDR1/BCRP coexpression remained significantly associated with a lower CR rate (p = 0.03), thereby identifying a clinically resistant subgroup of elderly AML patients...
  13. doi request reprint Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial
    Annemiek Broyl
    Department of Haematology, Erasmus MC, Rotterdam, Netherlands
    Lancet Oncol 11:1057-65. 2010
    ....
  14. ncbi request reprint Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncolo
    Gustaaf W van Imhoff
    Department of Hematology, University Medical Center Groningen, PO Box 30 001, 9700 RB Groningen, The Netherlands
    J Clin Oncol 23:3793-801. 2005
    ..Both trials had identical inclusion criteria and only differed in amount and duration of induction treatment before ASCT...
  15. doi request reprint High-dose daunorubicin in older patients with acute myeloid leukemia
    Bob Lowenberg
    Erasmus University Medical Center, Department of Hematology L413, P O Box 2040, 3000 CA Rotterdam, The Netherlands
    N Engl J Med 361:1235-48. 2009
    ..Daunorubicin is a cornerstone of the induction regimen, but the optimal dose is unknown. In older patients, it is usual to give daunorubicin at a dose of 45 to 50 mg per square meter of body-surface area...
  16. ncbi request reprint Various distinctive cytogenetic abnormalities in patients with acute myeloid leukaemia aged 60 years and older express adverse prognostic value: results from a prospective clinical trial
    Bronno van der Holt
    Department of Trials and Statistics HOVON Data Centre, Erasmus MC Daniel den Hoed Cancer Centre, Rotterdam, The Netherlands
    Br J Haematol 136:96-105. 2007
    ..Large studies to confirm the prognosis of individual cytogenetic aberrations are warranted...
  17. ncbi request reprint Economic evaluation of prophylactic granulocyte colony stimulating factor during chemotherapy in elderly patients with aggressive non-Hodgkin's lymphoma
    Jeanette K Doorduijn
    Department of Hematology, Erasmus MC Rotterdam, The Netherlands
    Haematologica 89:1109-17. 2004
    ..We analyzed the costs of therapy and follow-up of patients with NHL treated with CHOP with or without G-CSF prophylaxis...
  18. doi request reprint Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison
    Jan J Cornelissen
    Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Blood 113:1375-82. 2009
    ..This trial is registered with http://www.trialregister.nl under trial ID NTR228...
  19. doi request reprint High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group
    Noortje Thielen
    Department of Hematology, VU University Medical Center, De Boelelaan 1117, Amsterdam, The Netherlands
    Ann Hematol 92:1049-56. 2013
    ..However, the underpowering of the study precludes any definitive conclusions. This trial is registered at www.trialregister.nl (NTR674). ..
  20. doi request reprint High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance
    Annemiek Broyl
    Department of Hematology, Erasmus MC, Rotterdam, The Netherlands
    Blood 121:624-7. 2013
    ..trialregister.nl) as NTR213; at the European Union Drug Regulating Authorities Clinical Trials (EudraCT) as 2004-000944-26; and at the International Standard Randomized Controlled Trial Number (ISRCTN) as 64455289...
  21. pmc Unimpaired dendritic cell functions in MVP/LRP knockout mice
    Marieke H Mossink
    Department of Hematology, Erasmus Medical Center, Rotterdam, The Netherlands
    Immunology 110:58-65. 2003
    ..In conclusion, vaults are not required for primary DC functions. Their abundance in DCs may, however, still reflect basic roles in myeloid cell proliferation and DC development...
  22. doi request reprint Cytarabine dose for acute myeloid leukemia
    Bob Lowenberg
    Erasmus University Medical Center, Department of Hematology L413, P O Box 2040, 3000 CA Rotterdam, The Netherlands
    N Engl J Med 364:1027-36. 2011
    ..Intermediate dose levels have not been thoroughly evaluated...
  23. doi request reprint High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study
    Eduard J Libourel
    Department of Hematology, Erasmus University Medical Centre, Rotterdam, The Netherlands
    Blood 116:22-6. 2010
    ..Hypertension, smoking, and high factor VIII levels, possibly reflecting disease activity, contribute to the risk of arterial thrombosis...
  24. pmc Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia
    Wendy Deenik
    Erasmus University Medical Center, Rotterdam, The Netherlands
    Haematologica 95:914-21. 2010
    ....
  25. doi request reprint Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma
    Johannes J A Auwerda
    Erasmus University Medical Center, Department of Hematology, Rotterdam, The Netherlands
    Thromb Haemost 105:14-20. 2011
    ..4 [7.0-25.2], P<0.001). In conclusion, MP-TF activity is increased in patients with MM. Whether MP-TF activity has a pathogenetic role in VTE in MM patients remains to be established in future studies...
  26. ncbi request reprint Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma
    Ka Lung Wu
    Erasmus MC, Department of Haematology, Rotterdam, The Netherlands
    Br J Haematol 136:615-23. 2007
    ..In conclusion, chromosome 13 abnormalities and chromosome 1p and/or 1q abnormalities were highly associated, and are risk factors for poor outcome after intensive therapy in multiple myeloma...
  27. ncbi request reprint Induction therapy before transplantation in multiple myeloma: new strategies to achieve complete response
    Ka Lung Wu
    Department of Hematology, Erasmus Medical Center, 3000 CA Rotterdam, The Netherlands
    Clin Lymphoma Myeloma 6:96-101. 2005
    ..In this article, we review various regimens that are used for induction therapy in preparation for stem cell transplantation and describe the impact these novel agents could have on patient remission status...
  28. doi request reprint Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study
    Henk M Lokhorst
    Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands
    Blood 119:6219-25; quiz 6399. 2012
    ..These results do not support a general application of allo-SCT in all myeloma patients as part of first-line therapy...
  29. doi request reprint Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma
    Henk M Lokhorst
    Department of Hematology, University Medical Center, Utrecht, The Netherlands
    Haematologica 93:124-7. 2008
    ..However, CR plus VGPR were significantly higher in the patients randomized to TAD (49% vs. 32%, p<0.001). CTC grade 3-4 adverse events were similar in both arms...
  30. ncbi request reprint Cost analysis of common treatment options for indolent follicular non-Hodgkin's lymphoma
    Michel van Agthoven
    Institute for Medical Technology Assessment, Department of Health Policy and Management, Erasmus MC University Medical Centre, Rotterdam, The Netherlands
    Haematologica 90:1422-32. 2005
    ..We assessed direct health care costs associated with the most commonly prescribed treatments for indolent follicular non-Hodgkin's lymphoma (FL)...
  31. ncbi request reprint Efflux kinetics and intracellular distribution of daunorubicin are not affected by major vault protein/lung resistance-related protein (vault) expression
    Arend van Zon
    Department of Hematology, Erasmus Medical Center, 3000 DR Rotterdam, The Netherlands
    Cancer Res 64:4887-92. 2004
    ..Our results indicate that vaults are not directly involved in the sequestration of anthracyclines in vesicles nor in their efflux from the nucleus...
  32. ncbi request reprint Autologous bone marrow transplantation as consolidation therapy in the treatment of adult patients under 60 years with acute myeloid leukaemia in first complete remission: a prospective randomized Dutch-Belgian Haemato-Oncology Co-operative Group (HOVON)
    Dimitri A Breems
    Department of Haematology, Erasmus University Medical Centre, Rotterdam, The Netherlands
    Br J Haematol 128:59-65. 2005
    ..The results are discussed in relation to the generic problems of applying autologous transplantation and in the perspective of the limited statistical power of this and other previously published studies...
  33. pmc Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients
    Sophie L Corthals
    Erasmus Medical Center, Rotterdam, The Netherlands
    Haematologica 96:1728-32. 2011
    ..IFM 2005-01 clinicaltrials.gov identifier: NCT00200681; HOVON-65/GMMG-HD4 isrctn.org identifier: ISRCTN64455289)...
  34. ncbi request reprint ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients
    Bronno van der Holt
    Department of Trials and Statistics HOVON Dutch Belgian Hemato Oncology Cooperative Group Data Center, Erasmus MC Daniel den Hoed Cancer Center and Sophia Children s Hospital, Rotterdam, The Netherlands
    Clin Pharmacol Ther 80:427-39. 2006
    ....
  35. doi request reprint General aspects and mechanisms of peripheral neuropathy associated with bortezomib in patients with newly diagnosed multiple myeloma
    Annemiek Broyl
    Erasmus MC, Rotterdam, The Netherlands
    Semin Hematol 49:249-57. 2012
    ..Here, we discuss all aspects of bortezomib-induced peripheral neuropathy (BiPN), and elaborate on the mechanisms underlying the development of BiPN...
  36. ncbi request reprint Self-reported quality of life in elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy
    Jeanette Doorduijn
    Department of Hematology, Erasmus MC, Rotterdam, Netherlands
    Eur J Haematol 75:116-23. 2005
    ..The effect of CHOP on the quality of life of elderly patients could be used in counseling this group of patients...
  37. doi request reprint The expression of the peripheral cannabinoid receptor CB2 has no effect on clinical outcome in diffuse large B-cell lymphomas
    Nazik Rayman
    Departments of Hematology, Erasmus Medical Center, Rotterdam, The Netherlands
    Eur J Haematol 86:466-76. 2011
    ..This may be an explanation for the absence of prognostic relevance for the expression of this protein...
  38. doi request reprint Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy
    Pieter Sonneveld
    Department of Hematology, Erasmus Medical Center, Rotterdam, Netherlands
    Cancer 112:1529-37. 2008
    ....
  39. ncbi request reprint Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia
    Bob Lowenberg
    Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands
    N Engl J Med 349:743-52. 2003
    ..Sensitization of leukemic cells with hematopoietic growth factors may enhance the cytotoxicity of chemotherapy in acute myeloid leukemia (AML)...
  40. ncbi request reprint Pleomorphic presentation of cutaneous lesions associated with the proteasome inhibitor bortezomib in patients with multiple myeloma
    Ka Lung Wu
    Department of Hematology, Erasmus MC, Rotterdam, The Netherlands
    J Am Acad Dermatol 55:897-900. 2006
    ..One patient withdrew from further treatment because of severe cutaneous toxicity. The histologic findings ranged from perivascular dermatitis to interstitial and interface dermatitis corresponding with clinically more extensive lesions...
  41. doi request reprint Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens
    Adriana M W van Marion
    Department of Hematology, University Medical Center Utrecht, The Netherlands
    Leuk Res 32:1078-84. 2008
    ..Several coagulation abnormalities have been described in untreated myeloma patients, but these have not been prospectively evaluated during and after treatment...
  42. doi request reprint Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia
    Wendy Deenik
    Department of Hematology, Erasmus University Medical Center, Groene Hilledijk 301, Rotterdam, The Netherlands
    Blood 111:2581-8. 2008
    ..We conclude that combination therapy of escalating dosages of imatinib and cytarabine is feasible. This study was registered at www.kankerbestrijding.nl as no. CKTO-2001-03...
  43. pmc Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy
    Mark van Duin
    Department of Hematology, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands
    Haematologica 96:1662-9. 2011
    ....
  44. ncbi request reprint The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients
    Gert J Ossenkoppele
    Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands
    Blood 103:2908-13. 2004
    ..Although ARA-CTP accumulation in leukemic cells after FLAG was enhanced, clinical outcome in terms of CR rate, OS, EFS, and disease-free survival (DFS) was not significantly improved by combining fludarabine with ARA-C...
  45. ncbi request reprint The formation of vault-tubes: a dynamic interaction between vaults and vault PARP
    Arend van Zon
    Department of Hematology, Erasmus Medical Center, PO Box 1738, 3000 DR Rotterdam, The Netherlands
    J Cell Sci 116:4391-400. 2003
    ..The dynamics and structure of the tubes were examined using confocal microscopy. Our data indicate a direct and dynamic relationship between vaults and VPARP, providing further clues to unravel the function of vaults...
  46. ncbi request reprint Vaults: a ribonucleoprotein particle involved in drug resistance?
    Marieke H Mossink
    Department of Hematology, Erasmus Medical Center, PO Box 1738, 3000 DR Rotterdam, The Netherlands
    Oncogene 22:7458-67. 2003
    ..Here, we review the current knowledge on the vault complex and critically discuss the evidence that links vaults to drug resistance...
  47. doi request reprint Prognostic relevance of immunohistochemical subclassification of diffuse large B-cell lymphoma in two prospective phase III clinical trials
    Nazik Rayman
    Department of Hematology, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands
    Clin Lymphoma Myeloma Leuk 11:23-32. 2011
    ..Therefore, we have investigated the prognostic relevance of the immunohistochemical (IHC) germinal center B-cell (GCB) versus non-GCB diffuse large B-cell lymphoma (DLBCL) subtypes...
  48. doi request reprint Hematology: Lenalidomide plus dexamethasone is effective in multiple myeloma
    Ellen Meijer
    Department of Hematology, Erasmus University MC, Rotterdam, The Netherlands
    Nat Rev Clin Oncol 6:247-8. 2009
    ....
  49. doi request reprint First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial
    Anton Hagenbeek
    University Medical Center Utrecht, Department of Hematology, Utrecht, The Netherlands
    Blood 111:5486-95. 2008
    ..9 months at a median/maximum follow-up of 9.2/38.6 months. Ofatumumab is currently being evaluated in patients with rituximab-refractory FL. This trial was registered at www.clinicaltrials.gov as #NCT00092274...
  50. ncbi request reprint Successful treatment of systemic amyloidosis with hepatic involvement and factor X deficiency by high dose melphalan chemotherapy and autologous stem cell reinfusion
    Dimitri A Breems
    Department of Hematology, Erasmus Medical Center, Rotterdam, The Netherlands
    Eur J Haematol 72:181-5. 2004
    ..The diagnosis and treatment of systemic amyloidosis with hepatic involvement and the management of the multifactorial coagulopathy in these cases is discussed...
  51. ncbi request reprint Economic assessment in the management of non-Hodgkin's lymphoma
    Michel van Agthoven
    University Medical Centre Rotterdam, Erasmus MC, Institute for Medical Technology Assessment, PO Box 1738, 3000 DR Rotterdam, The Netherlands
    Expert Opin Pharmacother 5:2529-48. 2004
    ..Many NHL treatments remain to be studied in economic evaluations. Future publications should report on the six methodological items in more detail, and preferably tackle them in the recommended way...
  52. ncbi request reprint Sequential analysis of chromosome aberrations in multiple myeloma during disease progression
    Ka Lung Wu
    Department of Hematology, Erasmus Medical Center, Rotterdam, The Netherlands
    Clin Lymphoma Myeloma 7:280-5. 2007
    ..Herein, we report on sequential analysis of conventional cytogenetics as well as fluorescence in situ hybridization (FISH) data of 79 bone marrow specimens from 38 patients with myeloma who were longitudinally followed...
  53. doi request reprint Micro-RNA-15a and micro-RNA-16 expression and chromosome 13 deletions in multiple myeloma
    Sophie L Corthals
    Department of Hematology, Erasmus Medical Centre Rotterdam, Rotterdam, The Netherlands
    Leuk Res 34:677-81. 2010
    ..These findings suggest that genes other than miR-15a and miR-16 may explain the prognostic significance of 13q14 deletions...
  54. ncbi request reprint Prothrombotic coagulation abnormalities in patients with paraprotein-producing B-cell disorders
    Johannes J A Auwerda
    Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Clin Lymphoma Myeloma 7:462-6. 2007
    ..The aim of this study was to analyze prothrombotic coagulation disorders in patients with paraprotein-producing B-cell disorders, such as MGUS, systemic amyloidosis, Waldenström's macroglobulinemia, and MM...
  55. ncbi request reprint The expression of the peripheral cannabinoid receptor on cells of the immune system and non-Hodgkin's lymphomas
    Nazik Rayman
    Department of Hematology, Erasmus Medical Centre, Rotterdam, The Netherlands
    Leuk Lymphoma 48:1389-99. 2007
    ..We conclude that CB2 receptor expression pattern may be abnormal in NHL...
  56. doi request reprint Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients
    Annemiek Broyl
    Department of Hematology, Erasmus Medical Center and University, Rotterdam, The Netherlands
    Blood 116:2543-53. 2010
    ..To conclude, in addition to 7 clusters described in the UAMS classification, we identified 3 novel subsets of multiple myeloma that may represent unique diagnostic entities...
  57. ncbi request reprint A review of recruitment criteria, patient characteristics and results of CHOP chemotherapy in prospective randomized phase III clinical trials for aggressive non-Hodgkin's lymphoma
    Michel van Agthoven
    Erasmus Medical Center, University Medical Center, Institute for Medical Technology Assessment, Department of Health Policy and Management, Rotterdam, The Netherlands
    Hematol J 4:399-409. 2003
    ..We expect those factors to lead to a better consistency of results in future trials and improved possibilities to generalize the results...
  58. doi request reprint Novel anticancer agents for multiple myeloma: a review of the evidence for their therapeutic and economic value
    Jennifer G Gaultney
    Institute for Medical Technology Assessment Institute of Health Policy and Management, Erasmus University, PO Box 1738, 3000 DR Rotterdam, The Netherlands
    Expert Rev Anticancer Ther 12:839-54. 2012
    ..Future economic evaluations will require an assessment of the cost-effectiveness of these agents in terms of sequence within the treatment paradigm and in combination with one another...
  59. doi request reprint Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia
    Bob Lowenberg
    Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Blood 118:6030-6. 2011
    ..Toxicity was manageable and barasertib treatment resulted in an overall hematologic response rate of 25%. This study is registered at www.ClinicalTrials.gov as NCT00497991...
  60. ncbi request reprint Immunophenotyping as a guide for targeted therapy
    Pieter Sonneveld
    Department of Hematology, Erasmus MC, Room L407, P O Box 2040, 3000 CA, Rotterdam, The Netherlands
    Best Pract Res Clin Haematol 16:629-44. 2003
    ..The further development of these approaches is discussed...
  61. doi request reprint Phase I/II clinical study of Tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia
    Bob Lowenberg
    Department of Hematology, Erasmus University Medical Center, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    J Clin Oncol 28:4333-8. 2010
    ..To identify the maximum-tolerated dose (MTD) and to evaluate the antileukemic activity of tosedostat (formerly CHR-2797), an orally bioavailable aminopeptidase inhibitor...
  62. doi request reprint Screening for gastrointestinal malignancy in patients with iron deficiency anemia by general practitioners: an observational study
    Jolanda Droogendijk
    Department of Hematology, Erasmus Medical Center, Rotterdam, The Netherlands
    Scand J Gastroenterol 46:1105-10. 2011
    ..IDA is commonly caused by chronic gastrointestinal blood loss, and a thorough examination of the gastrointestinal tract must be standard practice...
  63. doi request reprint Treatment of relapsed and refractory multiple myeloma in the era of novel agents
    Niels W C J van de Donk
    Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands
    Cancer Treat Rev 37:266-83. 2011
    ..In this review we provide an overview of the various salvage regimens and give recommendations for treatment of patients with relapsed/refractory myeloma in different clinical settings...
  64. doi request reprint Risk and management of thrombosis in multiple myeloma
    Frank W G Leebeek
    Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Thromb Res 129:S88-92. 2012
    ..In addition we will focus on the prevention and management of arterial and venous thrombosis in patients with multiple myeloma...
  65. ncbi request reprint Partially T-cell-depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: a prospective evaluation of patients treated in the phase III study HOVON 24 MM
    Henk M Lokhorst
    Department of Hematology, University Medical Center Utrecht, HP G03 647, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands
    J Clin Oncol 21:1728-33. 2003
    ..To determine in a prospective study the efficacy, toxicity, and long-term outcome of up-front allogeneic stem-cell transplantation (allo-SCT) in multiple myeloma (MM)...
  66. ncbi request reprint Treatment of diffuse large B-cell lymphoma in the elderly: strategies integrating oncogeriatric themes
    Pieternella J Lugtenburg
    Department of Hematology, Erasmus MC, University Medical Center, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    Curr Oncol Rep 10:412-9. 2008
    ..This article reviews the efficacy and toxicity of the current treatment regimens applied for the treatment of diffuse large B-cell lymphoma in elderly patients and provides practical recommendations for the management of these patients...
  67. ncbi request reprint Genetic variations in the glucocorticoid receptor gene are not related to glucocorticoid resistance in childhood acute lymphoblastic leukemia
    Wim J E Tissing
    Department of Pediatric Oncology Hematology, Erasmus Medical Center Sophia Children s Hospital, Rotterdam, The Netherlands
    Clin Cancer Res 11:6050-6. 2005
    ..We analyzed whether genetic variations within the GR gene are related to differences in the cellular response to glucocorticoids...
  68. ncbi request reprint Disruption of the murine major vault protein (MVP/LRP) gene does not induce hypersensitivity to cytostatics
    Marieke H Mossink
    Department of Hematology, Erasmus University Rotterdam, 3015 GE Rotterdam, The Netherlands
    Cancer Res 62:7298-304. 2002
    ..Both groups of mice responded similarly to the doxorubicin treatment. Our results suggest that MVP/vaults are not directly involved in the resistance to cytostatic agents...
  69. ncbi request reprint Acquired lysosomal storage caused by frequent plasmapheresis procedures with hydroxyethyl starch
    Johannes J A Auwerda
    Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Transfusion 46:1705-11. 2006
    ..In case of massive tissue storage, this enzyme activity can reach levels comparable to those of Gaucher disease...
  70. ncbi request reprint International staging system for multiple myeloma
    Philip R Greipp
    Mayo Clinic College of Medicine and Eastern Cooperative Oncology Group, Rochester, MN, USA
    J Clin Oncol 23:3412-20. 2005
    ..There is a need for a simple, reliable staging system for multiple myeloma that can be applied internationally for patient classification and stratification...
  71. ncbi request reprint Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation
    Brian G M Durie
    Cedars Sinai Comprehensive Cancer Center, Los Angeles, CA, USA
    Hematol J 4:379-98. 2003
    ..2. Staging and prognostic factors. 3. Frontline therapy. 4. High-dose therapy and transplant. 5. Maintenance therapy. 6. Supportive care and management of specific complications. 7. Novel therapies and new technologies...
  72. ncbi request reprint Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients
    Maurizio Zangari
    The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
    Am J Hematol 82:831-3. 2007
    ..01). Markers of osteoblastic activation may predict quality and duration of response in multiple myeloma. In addition, our data suggest that bone anabolism could inhibit myeloma growth...
  73. ncbi request reprint Analysis of the efficacy and toxicity of bortezomib for treatment of relapsed or refractory multiple myeloma in community practice
    Ka Lung Wu
    Haematologica 90:996-7. 2005
    ..Here we report a multi-institutional analysis of the efficacy and toxicity of bortezomib in patients with relapsed or refractory multiple myeloma who were treated in community centers in a compassionate need program...
  74. ncbi request reprint Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma
    Paul G Richardson
    Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Br J Haematol 137:429-35. 2007
    ..Bortezomib should be considered an appropriate treatment for elderly and high-risk patients with relapsed multiple myeloma...
  75. ncbi request reprint Addition of cyclosporin A to the combination of mitoxantrone and etoposide to overcome resistance to chemotherapy in refractory or relapsing acute myeloid leukaemia: a randomised phase II trial from HOVON, the Dutch-Belgian Haemato-Oncology Working Group
    Simon Daenen
    Department of Haematology, University Hospital, Hanzeplein 1, 9713 GZ Groningen, The Netherlands
    Leuk Res 28:1057-67. 2004
    ..After a median follow-up of 66 months, six patients were still alive. Addition of CsA did not improve treatment outcome, possibly due to inadequate post-induction therapy as a result of increased toxicity...
  76. ncbi request reprint Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
    Paul G Richardson
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    N Engl J Med 352:2487-98. 2005
    ..This study compared bortezomib with high-dose dexamethasone in patients with relapsed multiple myeloma who had received one to three previous therapies...
  77. ncbi request reprint High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients
    Sahar Barjesteh van Waalwijk van Doorn-Khosrovani
    Institute of Hematology, Erasmus Medical Centre, Rotterdam, Netherlands
    Blood 101:837-45. 2003
    ..Our data demonstrate that high EVI1 expression is an independent poor prognostic marker within the intermediate- risk karyotypic group...
  78. ncbi request reprint Future directions in multiple myeloma treatment
    J Anthony Child
    General Infirmary and University of Leeds, Leeds, UK
    Acta Haematol 114:8-13. 2005
    ..The use of genetic profiles to further delineate groups for different treatment approaches should enable the introduction of patient-specific treatment programmes in the future...
  79. ncbi request reprint Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial
    Paul G Richardson
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 110:3557-60. 2007
    ..These data confirm the activity of bortezomib and support extended treatment in relapsed multiple myeloma patients tolerating therapy...
  80. doi request reprint Thalidomide for treatment of multiple myeloma: 10 years later
    Antonio Palumbo
    Division of Hematology, University of Torino, Azienda Ospedaliera S Giovanni Battista, Torino, Italy
    Blood 111:3968-77. 2008
    ..Future studies will define the most effective or the best sequence of combinations which could improve life expectancy...
  81. doi request reprint Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders
    Andy C Rawstron
    HMDS, Leeds Teaching Hospitals NHS Trust, Leeds, UK
    Haematologica 93:431-8. 2008
    ....
  82. ncbi request reprint Influence of genetic polymorphisms in CYP3A4, CYP3A5, GSTP1, GSTM1, GSTT1 and MDR1 genes on survival and therapy-related toxicity in multiple myeloma
    CĂ©line Schilthuizen
    Haematologica 92:277-8. 2007
    ..We observed no significant association between polymorphisms in CYP3A4, CYP3A5, MDR1, GSTM1 and GSTT1 and outcome either after treatment with induction chemotherapy or after high-dose therapy...
  83. ncbi request reprint Management of multiple myeloma with bortezomib: experts review the data and debate the issues
    Mario Dicato
    Department of Hematology Oncology, Luxembourg Medical Center, Luxembourg, Luxembourg
    Oncology 70:474-82. 2006
    ....
  84. doi request reprint Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study
    Asher Chanan-Khan
    Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    J Clin Oncol 26:4784-90. 2008
    ..The aim of this subset analysis was to determine if bortezomib treatment is associated with increased incidence of varicella-zoster virus (VZV) reactivation in patients with relapsed multiple myeloma (MM)...
  85. ncbi request reprint Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression
    Robert Z Orlowski
    Department of Medicine, Division of Hematology Oncology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7295, USA
    J Clin Oncol 25:3892-901. 2007
    ..This phase III international study compared the efficacy and safety of a combination of pegylated liposomal doxorubicin (PLD) plus bortezomib with bortezomib monotherapy in patients with relapsed or refractory multiple myeloma...
  86. ncbi request reprint A practical update on the use of bortezomib in the management of multiple myeloma
    Jesus San Miguel
    Hematology Department, Hospital Clinico Universitario de Salamanca, Servicio de Hematologia, Paseo de San Vicente 58, Salamanca E 37007, Spain
    Oncologist 11:51-61. 2006
    ..Information is given on the practical management of the most common adverse events, including peripheral neuropathy and thrombocytopenia, and the use of bortezomib in renal and hepatic impairment...
  87. ncbi request reprint Hypofibrinolysis during induction treatment of multiple myeloma may increase the risk of venous thrombosis
    Adriana M W van Marion
    Thromb Haemost 94:1341-3. 2005
  88. ncbi request reprint Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group
    William R Friedenberg
    Department of Hematology Oncology, Guthrie Foundation for Education and Research, Sayre, Pennsylvania, USA
    Cancer 106:830-8. 2006
    ....
  89. ncbi request reprint Phase II multicenter study of arsenic trioxide, ascorbic acid and dexamethasone in patients with relapsed or refractory multiple myeloma
    Ka Lung Wu
    Haematologica 91:1722-3. 2006
    ..Here we report the results of an international multi-center study of arsenic trioxide in combination with ascorbic acid and dexamethasone as treatment for patients with advanced multiple myeloma...
  90. ncbi request reprint Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib
    George Mulligan
    Clinical Research Translational Medicine, Millennium Pharmaceuticals Inc, 40 Landsdowne Street, Cambridge, MA 02139, USA
    Blood 109:3177-88. 2007
    ..Informative gene expression data and genomic classifiers that predict clinical outcome can be derived from prospective clinical trials of new anticancer agents...
  91. doi request reprint Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group
    Heinz Ludwig
    Department of Medicine, Wilhelminenspital, Montleartstr 37, 1160 Vienna, Austria
    Blood 111:4039-47. 2008
    ....
  92. ncbi request reprint Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma
    Johannes J A Auwerda
    Haematologica 92:279-80. 2007
    ..No difference in baseline coagulation parameters was found between patients with and without subsequent venous thromboembolism...
  93. doi request reprint Lenalidomide: a new therapy for multiple myeloma
    Antonio Palumbo
    Department of Hematology, University of Torino, Ospedale Molinette, Via Genova 3, 10126 Torino, Italy
    Cancer Treat Rev 34:283-91. 2008
    ....
  94. doi request reprint The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement
    M A Hussein
    Department of Hematologic Malignancies, H Lee Moffitt Cancer Center, Tampa, FL 33612, USA
    Leukemia 22:1479-84. 2008